Scientists test new HIV shot to train Body's defenses
NCT ID NCT06006546
Summary
This early-stage study is testing a new HIV vaccine candidate in 35 people already living with well-controlled HIV. The main goal is to see if the vaccine can safely trigger the body to produce a specific type of antibody that might fight the virus. To measure this, participants will temporarily pause their regular HIV medication under close medical supervision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HIV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlanta- Ponce
Atlanta, Georgia, 30303, United States
-
BIDMC
Boston, Massachusetts, 02215, United States
-
Birmingham
Birmingham, Alabama, 35294-2170, United States
-
Columbia P&S CRS Site#30329
New York, New York, 10032, United States
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Seattle Vaccine and Prevention CRS (Site # 30331)
Seattle, Washington, 98104, United States
-
The Hope Clinic of the Emory Vaccine Center CRS (Site #31440)
Decatur, Georgia, 30030, United States
-
University of Pittsburg
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.